Related Experiment Videos
Acquired factor X and antithrombin III deficiency in a patient with primary amyloidosis and nephrotic syndrome
Abstract:
A 45-year-old man with primary amyloidosis was initially seen with nephrotic syndrome. Factor X was found to be 5% and antithrombin III (AT III) 45% of normal plasma values. During an 11-month period, despite severe factor X deficiency, the patient did not have any bleeding complications. He developed progressive renal failure and AT III levels increased to normal, at which time he developed severe bleeding complications. These findings suggest a protective role of AT III deficiency against bleeding in a patient with severe factor X deficiency.
Insights
Severe factor X deficiency in a patient with primary amyloidosis did not cause bleeding. However, bleeding complications arose when antithrombin III (AT III) levels normalized, suggesting AT III deficiency protects against bleeding in factor X deficiency.
Area of Science:
- Hematology
- Nephrology
- Internal Medicine
Background:
- Primary amyloidosis can present with nephrotic syndrome and coagulation factor deficiencies.
- Factor X deficiency and antithrombin III (AT III) deficiency are rare but significant hemostatic challenges.
Observation:
- A 45-year-old male with primary amyloidosis and nephrotic syndrome presented with severely reduced Factor X (5%) and AT III (45%) levels.
- Despite profound Factor X deficiency, the patient experienced no bleeding complications over an 11-month period.
- As renal failure progressed, AT III levels normalized, coinciding with the onset of severe bleeding complications.
Findings:
- The case suggests that concurrent AT III deficiency may mitigate the bleeding risk associated with severe Factor X deficiency.
- The interplay between Factor X and AT III in hemostasis is complex and context-dependent.
Implications:
- This observation challenges conventional understanding of bleeding risk in combined Factor X and AT III deficiencies.
- Further research into the protective mechanisms of AT III deficiency in Factor X deficiency is warranted.
- Understanding these interactions is crucial for managing patients with amyloidosis and associated coagulopathies.